59
We report a case of reversible encephalopathy syndrome in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin.
 a 16-year-old girl with acute myelogenous leukemia (AML): Subject; 16-year-old: Subject.Age; girl: Subject.Gender; reversible encephalopathy syndrome: Effect; consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin: Treatment; acute myelogenous leukemia: Treatment.Disorder; idarubicin: Treatment.Drug; BH-AC: Treatment.Drug; idarubicin: Combination.Drug; BH-AC: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 a 16-year-old girl with acute myelogenous leukemia (AML): Subject; 16-year-old: Subject.Age; girl: Subject.Gender; reversible encephalopathy syndrome: Effect; consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin: Treatment; acute myelogenous leukemia: Treatment.Disorder; idarubicin: Treatment.Drug; BH-AC: Treatment.Drug; idarubicin: Combination.Drug; BH-AC: Combination.Drug